Ligand Eyes Pharmacopeia Royalty Stream In Merger Deal
This article was originally published in The Pink Sheet Daily
Executive Summary
Stock-for-stock exchange is valued at $70 million, though DARA future still unclear.
You may also be interested in...
Ligand Takes Out Neurogen For At Least $11 Million
Continuing its rebound from the Third Point fight, Ligand issues a sliver of stock to take control of Neurogen.
Ligand Takes Out Neurogen For At Least $11 Million
Continuing its rebound from the Third Point fight, Ligand issues a sliver of stock to take control of Neurogen.
Roche Snaps Up Memory, Gains CNS Drugs
Swiss drugmaker gains partnered compounds in Alzheimer’s and schizophrenia via $50 million deal.